AU2020214258B2 - AKT inhibitor - Google Patents

AKT inhibitor

Info

Publication number
AU2020214258B2
AU2020214258B2 AU2020214258A AU2020214258A AU2020214258B2 AU 2020214258 B2 AU2020214258 B2 AU 2020214258B2 AU 2020214258 A AU2020214258 A AU 2020214258A AU 2020214258 A AU2020214258 A AU 2020214258A AU 2020214258 B2 AU2020214258 B2 AU 2020214258B2
Authority
AU
Australia
Prior art keywords
compound
formula
methyl
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020214258A
Other languages
English (en)
Other versions
AU2020214258A1 (en
Inventor
Jie An
Donghui Chen
Changyou MA
He Tian
Zhoushan TIAN
Jian Wu
Dan Xu
Jianliang Zhao
Chunxia ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Publication of AU2020214258A1 publication Critical patent/AU2020214258A1/en
Application granted granted Critical
Publication of AU2020214258B2 publication Critical patent/AU2020214258B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020214258A 2019-01-29 2020-01-22 AKT inhibitor Active AU2020214258B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910084801.3 2019-01-29
CN201910084801 2019-01-29
PCT/CN2020/073798 WO2020156437A1 (zh) 2019-01-29 2020-01-22 Akt抑制剂

Publications (2)

Publication Number Publication Date
AU2020214258A1 AU2020214258A1 (en) 2021-09-16
AU2020214258B2 true AU2020214258B2 (en) 2025-08-28

Family

ID=71841634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020214258A Active AU2020214258B2 (en) 2019-01-29 2020-01-22 AKT inhibitor

Country Status (10)

Country Link
US (1) US20220144821A1 (https=)
EP (1) EP3919491B1 (https=)
JP (2) JP7617005B2 (https=)
KR (1) KR102892239B1 (https=)
CN (2) CN117964620A (https=)
AU (1) AU2020214258B2 (https=)
CA (1) CA3127884A1 (https=)
ES (1) ES3037595T3 (https=)
PL (1) PL3919491T3 (https=)
WO (1) WO2020156437A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI908780B (zh) * 2020-03-17 2025-12-21 大陸商江蘇恆瑞醫藥股份有限公司 稠合二環類衍生物、其製備方法及其在醫藥上的應用
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
CN119302960A (zh) * 2020-07-22 2025-01-14 南京正大天晴制药有限公司 Akt抑制剂的单位剂量组合物
WO2022017448A1 (zh) * 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN115836069B (zh) * 2020-07-22 2024-02-06 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
CN116478156A (zh) * 2022-01-17 2023-07-25 南京正大天晴制药有限公司 一种akt抑制剂化合物的富马酸盐晶型及其制备方法
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN121586576A (zh) 2023-06-14 2026-02-27 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用
CN121177294B (zh) * 2025-11-27 2026-02-27 四川省医学科学院·四川省人民医院 Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
WO2009089462A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
WO2014078637A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065908A1 (en) * 2009-12-07 2013-03-14 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
EP2049500B1 (en) 2006-07-06 2011-09-07 Array Biopharma, Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
AR093511A1 (es) * 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN108503645A (zh) * 2018-03-01 2018-09-07 山东大学 含氨甲基的哌嗪酮类化合物及其制备方法和应用
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
WO2009089462A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
WO2014078637A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 4 July 2005 (2005-07-04), "1-Propanone, 2-amino-3-(4-chlorophenyl)-1-[4-(5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-4-yl)-1-piperazinyl]-, (2R)-(CA INDEX NAME)", retrieved from STN Database accession no. 853686-96-1 *

Also Published As

Publication number Publication date
US20220144821A1 (en) 2022-05-12
CN113272304B (zh) 2024-03-29
KR102892239B1 (ko) 2025-11-26
EP3919491A1 (en) 2021-12-08
JP7617005B2 (ja) 2025-01-17
EP3919491A4 (en) 2022-10-19
WO2020156437A1 (zh) 2020-08-06
PL3919491T3 (pl) 2025-10-20
EP3919491C0 (en) 2025-05-28
CN117964620A (zh) 2024-05-03
KR20210120054A (ko) 2021-10-06
EP3919491B1 (en) 2025-05-28
CN113272304A (zh) 2021-08-17
AU2020214258A1 (en) 2021-09-16
CA3127884A1 (en) 2020-08-06
ES3037595T3 (en) 2025-10-03
JP2024175091A (ja) 2024-12-17
JP2022517866A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
AU2020214258B2 (en) AKT inhibitor
AU2020350745B2 (en) Fused pyridone compound, and preparation method therefor and use thereof
AU2019309987B2 (en) Heterobicyclic compounds for inhibiting the activity of shp2
AU2020337938B2 (en) KRas G12D inhibitors
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
US11286248B2 (en) Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
AU2014400628B2 (en) Aminopyridazinone compounds as protein kinase inhibitors
AU2008304417B2 (en) Polo-like kinase inhibitors
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
US20090291938A1 (en) Polo-like kinase inhibitors
WO2020221294A1 (zh) 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
US20240140951A1 (en) Imidazopyridazine derivatives as il-17 modulators
CN105712998B (zh) 氮杂吲哚类衍生物、其制备方法及其在医药上的应用
WO2011152485A1 (ja) 新規４，５－縮環ピリミジン誘導体
JP7698064B2 (ja) 抗腫瘍活性を有する化合物及びその使用
TWI902994B (zh) Ｉｒａｋ４抑制劑、藥物組成物及其用途
CN115916350B (zh) Akt抑制剂的单位剂量组合物
CN115485276B (zh) 氘代akt激酶抑制剂
CA3028824C (en) Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
JP2024518784A (ja) 含窒素複素環式化合物
US20230312564A1 (en) Aromatic ring-lactam compound, preparation method therefor and use thereof
EP4038072A1 (en) Mcl1 inhibitors and uses thereof
HK40050826B (zh) Akt抑制剂
KR102958021B1 (ko) 피리다지닐 티아졸카르복시아미드 화합물
US12612408B2 (en) Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)